To evaluate whether 6-, 9-, and 12-month rates of persistency (long-term compliance) with initially prescribed antipsychotic monotherapy translate into cost savings. METHODS: We identified 220 newly diagnosed psychotic patients from approximately 180 managed care organizations who were initiated on quetiapine monotherapy during an 18-month period. Patients were randomly selected and matched by study date to populate three comparator groups: a haloperidol group; a risperidone group, and patients initiated on any atypical agent except quetiapine. Patients were tracked for at least one year to identify whether they remained on monotherapy, added to the therapy, switched, or discontinued it. Psychiatric costs were aggregated by service type. Analyses included tests of proportions for rates, Cox proportional hazard models for time, and linear regressions for cost. 
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